Gabapentin Capsule
Product Images NDC 60760-669

7 FDA label images from St. Mary's Medical Park Pharmacy · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 60760-669). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by St. Mary's Medical Park Pharmacy, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Equation (Equation)

Equation (Equation)
An equation illustrating the calculation of creatinine clearance (CLCr) based on age, weight, serum creatinine, and an adjustment factor for female patients. The formula is shown as [(140 - age in years) x weight in kg] divided by [72 x serum creatinine in mg/dL], multiplied by 0.85 for female patients.*
FDA Label Image

Structure (Struct)

Structure (Struct)
Chemical structure diagram of gabapentin showing a cyclohexane ring attached to an aminomethyl and a carboxymethyl group.*
FDA Label Image

Fig 1 (Fig 1)

Fig 1 (Fig 1)
A line graph titled 'Weekly Mean Pain Scores' displaying mean pain scores over 8 weeks in a study population. The x-axis represents weeks from baseline to 8, and the y-axis shows mean pain scores ranging from 0 to 10. Two lines compare placebo and gabapentin (3600 mg/day), showing gabapentin with a decreasing pain score trend over time versus a relatively stable score for placebo.*
FDA Label Image

Fig 2 (Fig 2)

Fig 2 (Fig 2)
A line graph titled 'Weekly Mean Pain Scores (Observed Cases in ITT Population): Study 2' showing mean pain scores over 7 weeks. It compares three groups: placebo, Gabapentin 1800 mg/day, and Gabapentin 2400 mg/day, with mean pain scores decreasing over time for gabapentin groups compared to placebo.*
FDA Label Image

Fig 3 (Fig 3)

Fig 3 (Fig 3)
A bar chart titled 'Proportion of Responders (patients with ≥50% reduction in pain score) at Endpoint: Controlled PHN Studies' comparing the percentage of responders between placebo (PBO) and gabapentin (GBP) doses across two studies. Study 1 shows 12% responders for placebo and 29% for GBP 3600 mg. Study 2 shows 14% for placebo, 32% for GBP 1800 mg, and 34% for GBP 2400 mg, with statistical significance indicated.*
FDA Label Image

Fig 4 (Fig 4)

Fig 4 (Fig 4)
A bar chart showing responder rates expressed as a difference from placebo in percentage among patients aged 12 years and older with partial seizures, across three studies labeled a, b, and c. The x-axis represents daily doses of gabapentin in milligrams (600, 900, 1200, 1800 mg), and the y-axis shows the percentage difference in response rate.*
FDA Label Image

669 (Gabapentin 60760 669 30)

669 (Gabapentin 60760 669 30)
Label for Gabapentin capsules, USP 100 mg, with a quantity of 30 capsules. The label includes the NDC 60760-669-30, mentions manufacturing by HETERO in Kolar, Karnataka, India, and packaging by St. Mary's Medical Park Pharmacy, Oro Valley, AZ. It instructs to use as directed and store at controlled room temperature 15°-30°C (59°-86°F). Lot number and expiration date are shown as placeholders.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.